Navigation Links
GenVec Announces Third Quarter 2009 Results Conference Call
Date:10/28/2009

GAITHERSBURG, Md., Oct. 28 /PRNewswire-FirstCall/ -- GenVec, Inc. (Nasdaq: GNVC) announced that it will release financial results for the third quarter ended September 30, 2009 on Thursday, November 5, 2009 after market close. GenVec will hold a conference call at 10:00 a.m. EST on Friday, November 6, 2009 to discuss the company's third quarter results.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081205/DC50112LOGO )

To listen to the live conference call, please dial 888-679-8040 (U.S. or Canada) or 617-213-4851 (international) and use access code 35178683. Participants may pre-register for the call anytime at:

https://www.theconferencingservice.com/prereg/key.process?key=PPCBK3H6R.

Pre-registrants will be issued a PIN number to use when dialing into the live call, which will provide quick access to the conference. An audio replay of the conference call will be available starting at 1:00 p.m. on November 6, 2009 through November 12, 2009. To listen to the audio replay, dial 888-286-8010 (U.S. or Canada) or 617-801-6888 (international) and use access code 28987203.

A live webcast of the conference call will be available on the Company's website and will be archived for 30 days. To access the webcast or the replay, go to www.genvec.com, click on "Investor Relations," and click on "Webcasts and Data."

About GenVec

GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec's lead product, TNFerade(TM), is currently in a pivotal clinical study (PACT) in locally advanced pancreatic cancer. TNFerade has also been and is currently being evaluated for its potential use in the treatment of several other cancers, including esophageal cancer, rectal cancer, and head and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and HSV-2. Additional information about GenVec is available at www.genvec.com and in the company's various filings with the Securities and Exchange Commission.

    Investor Contact:            Media Contact:
    GenVec, Inc.                 Tiberend Strategic Advisors, Inc.
    Danielle M. DiPirro          Andrew Mielach
    (301) 944-1877               (212) 827-0020
    ddipirro@genvec.com          amielach@tiberendstrategicadvisors.com

SOURCE GenVec, Inc.


'/>"/>
SOURCE GenVec, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants
2. GenVec Receives an Approximately $2.5 Million Grant to Support Novel Cell Line Development
3. GenVec Reports Second Quarter 2009 Financial Results
4. GenVec Expands Contract Supporting Malaria Vaccine Program
5. GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants
6. Medivation Announces Third Quarter 2009 Financial Results Teleconference and Webcast on November 4, 2009
7. TOPAZ Technologies Announces SoBran Inc. as New Customer
8. Oncolytics(R) Biotech Inc. Announces Issuance of 33rd U.S. Patent
9. LPBP Inc. announces final distribution
10. Pulmo BioTech Inc. Announces Cash Details of its Previously Announced Letter of Intent Intended to Bring its Pulmonary Vascular Diagnostic Product Candidate PulmoBind(TM) to the European Market
11. Myriant Technologies LLC Announces Appointment of Science Advisory Board Members
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... January 18, 2017 , ... Opal Kelly, a leading ... PCI Express, announced the ZEM5310 USB 3.0 FPGA Module, combining a SuperSpeed USB ... sized form factor suitable for prototyping, testing, and production-ready integration. The ZEM5310 USB ...
(Date:1/18/2017)... , Jan. 18, 2017   Boston Biomedical ... compounds designed to target cancer stemness pathways, will feature ... compound, napabucasin, at the 2017 ASCO Gastrointestinal Cancers Symposium, ... . Napabucasin is an orally-administered ... targeting STAT3. i Cancer stem cells (CSCs) possess ...
(Date:1/18/2017)... 2017   Parent Project Muscular Dystrophy (PPMD) , ... Duchenne muscular dystrophy (Duchenne) , today announced a $600,000 ... of Technology (NJIT) and Talem Technologies (Talem) as part ... to assist people living with Duchenne. PPMD is ... an embedded computer, software, a force sensor and a ...
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... ... that Dr. Dante Leven successfully implanted SpineFrontier’s A-CIFT™ Solofuse-P™. The operation took place ... in Valley Stream, NY. The procedure was an anterior cervical discectomy and fusion ...
Breaking Biology Technology:
(Date:12/22/2016)... December 22, 2016 SuperCom (NASDAQ: ... solutions for the e-Government, Public Safety, HealthCare, and Finance sectors announced ... has been selected to implement and deploy a community-based supportive services ... Northern California , further expanding its presence in the state. ... This new program, ...
(Date:12/19/2016)... España y TORONTO , 19 de diciembre de ... Biologics Inc. que permitirá el desarrollo acelerado de MSC-1, un anticuerpo ... varios tipos de tumor en 2017, con múltiples sitios previstos a ... ... con objetivo en el factor inhibidor de leucemia (LIF), una citoquina ...
(Date:12/16/2016)... 2016 The global wearable medical device market, in terms ... from USD 5.31 billion in 2016, at a CAGR of 18.0% ... ... advancements in medical devices, launch of a growing number of smartphone-based ... among healthcare providers, and increasing focus on physical fitness. ...
Breaking Biology News(10 mins):